I-Mab Presents Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025

Barchart · 07/02 10:15

Data show confirmed ORR of 83% (10/12) at doses selected for ongoing expansion study

Median follow-up of 9.0 months as of the updated data cutoff

Read more at globenewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.